Announcements Trials

Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 2 Withdrawn 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 10 Brain Neoplasms 3 Urogenital Diseases 2 Neoplasms 2 Glioblastoma 2 Disease 2 Squamous Cell Carcinoma of Head and Neck 1 Neoplasm Metastasis 1 Metastatic Castration-resistant Prostate Cancer 1 Glioma 1 Carcinoma, Lobular 1 Breast Neoplasms 1

Interventions

Temozolomide 88 Bevacizumab 49 Radiotherapy 36 Irinotecan 22 Magnetic Resonance Spectroscopy 20 Surgical Procedures, Operative 17 Carboplatin 17 Carmustine 15 Radiation 13 Nivolumab 11 IL13-PE38 8 Erlotinib Hydrochloride 8 Thalidomide 7 Radiotherapy, Intensity-Modulated 7 Lomustine 7 Imatinib Mesylate 7 Everolimus 7 Aminolevulinic Acid 7 sargramostim 6 Topotecan 6 O(6)-benzylguanine 6 Cyclophosphamide 6 Chemotherapy, Adjuvant 6 vandetanib 5 temsirolimus 5 fluorodopa F 18 5 Vincristine 5 Surveys and Questionnaires 5 Radiosurgery 5 Flucytosine 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Glioma × fluciclovine F-18 × Clear all

NCT04114370 2022-12-06

FACBC

University of Pittsburgh

Phase EARLY_PHASE1 Completed

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡